Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2037731 | 1.00 | HSD11B1 (0.60) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL22680068 | 1.00 | HSD11B1 (0.60) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL5822208 | 0.92 | HSD11B1 (0.68) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL470552 | 0.92 | HSD11B1 (0.68) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL8296190 | 0.92 | HSD11B1 (0.68) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL2897115 | 0.91 | CA1 (0.62) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL28767041 | 0.91 | CA1 (0.62) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL27694125 | 0.91 | CA1 (0.62) | HSD11B1CYP2C9EPHX1USP30CTSK | |
| SCHEMBL2016955 | 0.91 | EPHX1 (0.68) | HSD11B1CYP2C9EPHX1CTSKCA1 | |
| SCHEMBL15084767 | 0.88 | HSD11B1 (0.57) | HSD11B1CYP2C9EPHX1USP30CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886814-A | PD-1/PD-L1 small molecule inhibitor and application thereof in medicines | 广东东阳光药业股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| EP-2231646-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076387-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076387-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | HSD11B1 791/4885CYP2C9 1222/4885EPHX1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.